Clinical trial
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
NCT04201756 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma: A Single-Arm, Open-Label, Phase II Clinical Trial
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 26, 2020
- Completion date
- August 30, 2022
- Enrollment
- 47 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
egfr gene mutation, lung adenocarcinoma stage iii